Ulimorelin
A ghrelin agonist that moved the stomach but not the colon
Ulimorelin is an investigational macrocyclic drug that activates the ghrelin receptor, which stimulates gut movement. Developed to shorten the gut shutdown that follows bowel surgery, it looked promising in a phase 2 trial, but two phase 3 trials found no benefit. A later study showed why: it speeds stomach emptying but has no measurable effect on the colon.
Used in human trials: 160 or 480 µg/kg, Once daily, 30-minute infusion, Intravenous (Phase 3: postoperative ileus) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Ghrelin, the hunger hormone, also stimulates the gut. Ulimorelin came from a screening programme of macrocyclic compounds against the human ghrelin receptor, optimised for potency and pharmacokinetics. It was developed for postoperative ileus, the temporary paralysis of the bowel after abdominal surgery that keeps patients in hospital.
In people it was always given as a 30-minute intravenous infusion. In 48 healthy volunteers, single doses from 20 to 600 µg/kg were well tolerated, though the top dose slowed the heart in two people and higher doses lowered blood pressure for about an hour. It lasts a long time for a ghrelin agonist, with a half-life of 10 to 20 hours, and binds almost completely to blood proteins, so exposure rises less than the dose does.
In phase 2, the most effective dose (480 µg/kg) shortened time to gastrointestinal recovery after colectomy, an effect that remained significant after adjusting for surgery type and opioid use (hazard ratio 1.81). But in two phase 3 trials, of 332 and 330 patients, neither dose differed from placebo on the primary endpoint or on time to first bowel movement, tolerating solid food or discharge eligibility. Serious adverse events were similar across groups.
A 2020 human study offered an explanation. Ulimorelin sped liquid gastric emptying by 23% to 46%, but had no effect on colonic transit, and the authors suggested the free drug levels and dosing frequency in the ileus trials may have been too low. In rats, it drives colorectal propulsion through the lumbosacral spinal cord, and in rodents and humans it lowers blood pressure and dilates vessels through actions independent of the ghrelin receptor.
Gastroparesis was the other target. In 10 adults with diabetic gastroparesis it sped solid-meal emptying by 20%, and in a four-day trial in 76 inpatients a daily 80 µg/kg infusion eased appetite loss, vomiting and fullness more than placebo; a subset with severe vomiting went from about three vomiting days in four to about one. Those trials were small and short, and the programme did not continue to an approval.
Mechanism of Action
Ulimorelin is a ring-shaped peptidomimetic that activates the ghrelin receptor (GHS-R1a). In the gut that speeds the stomach and, in rats, drives colorectal propulsion through nerves in the lower spinal cord; separately, it relaxes blood vessels through actions that do not need the ghrelin receptor.
Stomach emptying
It sped solid and liquid gastric emptying in people, including those with diabetic gastroparesis.
Lower bowel
In rats it drove colorectal propulsion through lumbosacral spinal pathways; in people, colonic transit did not change.
Blood pressure
It lowered blood pressure and heart rate at higher doses, and dilated vessels independently of the ghrelin receptor.
Protein binding
At least 99% bound to plasma proteins, which limits free drug and may explain weak effects at trial doses.
Published Research
Studies of ulimorelin, from their PubMed abstracts.
Two phase 3 trials in postoperative ileus
In studies 007 (332 patients) and 008 (330), neither dose of ulimorelin differed from placebo on the primary endpoint or on time to first bowel movement, tolerance of solid food or discharge eligibility; serious adverse events were comparable.
Phase 2 after colectomy
At 480 µg/kg, the most effective dose, ulimorelin shortened time to gastrointestinal recovery after adjustment for surgery type and opioid use (hazard ratio 1.81, P = 0.014).
Stomach yes, colon no
Doses of 150-600 µg/kg every 8 hours sped liquid gastric emptying by 23% to 46% through day 6 but did not change colonic transit; the authors suggested drug levels in the ileus trials may have been inadequate.
Feeding intolerance in intensive care
In 120 critically ill patients with enteral feeding intolerance, ulimorelin and metoclopramide achieved similar shares of the feeding target over 5 days (median 82.9% against 82.3%) and similar feeding success, with no safety differences.
Phase 2b dose-ranging after colectomy
In 236 adults after open partial colectomy, daily 30-minute infusions of 20 to 600 µg/kg for up to 7 days shortened median time to first bowel movement by 10 to 22 hours against placebo. At 480 µg/kg, the most effective dose, readiness for discharge came 20.4 hours sooner (hazard ratio 1.69), and nausea and vomiting were less common than on placebo.
First in humans
In 48 healthy volunteers given single 30-minute infusions of 20 to 600 µg/kg or placebo, it was well tolerated; two people at the top dose had slow heart rates, and blood pressure and heart rate dipped about an hour after higher doses. Its half-life was about 13 hours, and receptor activity showed from 40 µg/kg.
Protein binding and pharmacokinetics
In healthy volunteers and people with gastroparesis, exposure rose less than in proportion to dose, which the authors traced to binding of 99% or more to plasma proteins, mainly alpha-1-acid glycoprotein. Half-life was 10 to 20 hours, and binding was higher in human plasma than in any animal species tested.
Gastric emptying in diabetic gastroparesis
In a crossover study in 10 adults with diabetes and gastroparesis, infusions of 80 to 600 µg/kg cut solid-meal half-emptying time by 20% and lag time by 34% against placebo. Symptom improvements were not statistically significant.
Symptoms in diabetic gastroparesis
In 76 inpatients randomised to one of six doses or placebo, given as a daily 30-minute infusion for four days, 80 µg/kg was the most effective dose, improving loss of appetite, vomiting and fullness scores against placebo. Safety was similar across groups.
Severe nausea and vomiting subset
Among 23 patients from that trial with severe nausea and vomiting, 80 µg/kg cut the days with vomiting from a mean of 3.2 to 1.2 of four treatment days and improved symptom scores, with part of the benefit still present at 30 days. It is a small post hoc subset.
How it drives defecation in rats
Intravenous ulimorelin caused about an hour of increased colorectal propulsion, prevented by cutting lumbosacral nerves, by hexamethonium or by ghrelin receptor antagonists, and mimicked by applying it to the lumbosacral spinal cord.
Effects on blood vessels
Ulimorelin, which lowers blood pressure in rodents and humans, dilated rodent arteries through mechanisms independent of the ghrelin receptor.
Bowel recovery in rats after surgery
In rats given morphine and abdominal surgery, three intravenous doses of 0.03 to 1 mg/kg over four hours shortened time to first bowel movement and raised faecal output in a dose-dependent way without changing food intake.
From screening hit to clinic
Ulimorelin came out of a screen of a macrocycle library against the human ghrelin receptor. Rigidifying the ring improved potency (Ki 16 nM, EC50 29 nM) and pharmacokinetics; the paper reports 24% oral bioavailability in its preclinical testing, though the human trials used intravenous infusion.
Dosing Data
Ulimorelin was never approved. Every dose on record is a hospital intravenous infusion given in a clinical trial.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no regulator's label that says in what form Ulimorelin is supplied. It is prepared and given by clinical staff, not bought and mixed at home: the next part says where.
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Ulimorelin is prepared and given by clinical staff, in hospital, after surgery or in intensive care.
In the carded studies it was given into a vein after bowel surgery and to critically ill patients on tube feeding.
Source: PMID 22072430 and PMID 31062046 (studies carded under Research below).
Storage before and after mixing
Unknown: no label on file says how Ulimorelin is stored. It is kept and prepared by the hospital or clinic that gives it (see the part above); the home rules for a mixed vial in the mixing guide do not apply to it.
How it is taken
As it was given in human studies: Intravenous (Once daily, 30-minute infusion; Phase 3: postoperative ileus).
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Phase 3: postoperative ileus: Up to 7 days; Phase 2b: ileus after colectomy: Up to 7 days; Phase 2: diabetic gastroparesis: 4 days.
When effects appear: unknown; no source on this page gives a time to effect for Ulimorelin. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Serious adverse events comparable to placebo in phase 3; Blood pressure lowering reported in rodents and humans; Slow heart rate in two volunteers at the 600 µg/kg dose; Mostly mild, self-limiting events in gastroparesis trials, similar to placebo. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Ulimorelin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
Unknown: a PubMed search for human interaction studies of Ulimorelin (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Ulimorelin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: In Clinical Trials (Not approved anywhere). Sport: Prohibited (S0 catch-all).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
No label; it is investigational.
Legal Status
Ulimorelin is investigational.
Frequently Asked Questions
?What was ulimorelin for?
Shortening postoperative ileus, the temporary shutdown of the bowel after abdominal surgery, by activating the ghrelin receptor.
?Why did it fail?
Two phase 3 trials found no benefit over placebo. A later study showed it speeds stomach emptying but not colonic transit, and the authors suggested the doses in the ileus trials may have been too low.
?Is ulimorelin a peptide?
It is a macrocyclic peptidomimetic: a ring-shaped molecule designed to act on the ghrelin receptor rather than a natural peptide.
?Does it affect blood pressure?
Yes: it lowers blood pressure in rodents and humans, and rodent studies show it dilates arteries through mechanisms that do not depend on the ghrelin receptor.
?What dose of ulimorelin was used in trials?
After bowel surgery, 160 or 480 µg/kg once daily as a 30-minute infusion for up to 7 days; in diabetic gastroparesis, 80 µg/kg daily for four days worked best. These were hospital trial doses; it is not approved.
?Did ulimorelin help gastroparesis?
In small, short trials it sped stomach emptying and eased vomiting and appetite loss at 80 µg/kg. The programme did not reach approval.
References
- [clinical-trial] Shaw M, et al. "Safety and efficacy of ulimorelin administered postoperatively to accelerate recovery of gastrointestinal motility following partial bowel resection: results of two randomized, placebo-controlled phase 3 trials." Dis Colon Rectum, 2013;56(7):888-97. PMID: 23739196.
- [clinical-trial] Bochicchio G, et al. "Ghrelin agonist TZP-101/ulimorelin accelerates gastrointestinal recovery independently of opioid use and surgery type: covariate analysis of phase 2 data." World J Surg, 2012;36(1):39-45. PMID: 22072430.
- [clinical-trial] James J, et al. "The effects of ulimorelin, a ghrelin agonist, on liquid gastric emptying and colonic transit in humans." Neurogastroenterol Motil, 2020;32(3):e13784. PMID: 32017341.
- [pubmed] Pustovit RV, et al. "The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin." Neurogastroenterol Motil, 2014;26(2):264-71. PMID: 24304447.
- [pubmed] Broad J, et al. "Analysis of the ghrelin receptor-independent vascular actions of ulimorelin." Eur J Pharmacol, 2015;752:34-9. PMID: 25687251.
- [clinical-trial] Heyland DK, et al. "A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial." Intensive Care Med, 2019;45(5):647-656. PMID: 31062046.
- [clinical-trial] Popescu I, et al. "The Ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial." Dis Colon Rectum, 2010;53(2):126-34. PMID: 20087086.
- [clinical-trial] Lasseter KC, et al. "Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study." J Clin Pharmacol, 2008;48(2):193-202. PMID: 18199894.
- [clinical-trial] Wargin W, et al. "Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study." Clin Drug Investig, 2009;29(6):409-18. PMID: 19432500.
- [clinical-trial] Ejskjaer N, et al. "Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis." Aliment Pharmacol Ther, 2009;29(11):1179-87. PMID: 19298585.
- [clinical-trial] Ejskjaer N, et al. "Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study." Neurogastroenterol Motil, 2010;22(10):1069-e281. PMID: 20524987.
- [clinical-trial] Wo JM, et al. "Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data." Aliment Pharmacol Ther, 2011;33(6):679-88. PMID: 21214610.
- [pubmed] Fraser GL, et al. "Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus." Eur J Pharmacol, 2009;604(1-3):132-7. PMID: 19121631.
- [pubmed] Hoveyda HR, et al. "Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic." J Med Chem, 2011;54(24):8305-20. PMID: 22106937.
Sources & Citations
Studies were read from their PubMed records, October 3 and October 16, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.